Cen Biotech Stock Analysis
| CENBF Stock | USD 0.0001 0.00 0.00% |
CEN Biotech's financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. CEN Biotech's financial risk is the risk to CEN Biotech stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that CEN Biotech's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which CEN Biotech is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of CEN Biotech to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, CEN Biotech is said to be less leveraged. If creditors hold a majority of CEN Biotech's assets, the Company is said to be highly leveraged.
CEN Biotech is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of CEN Biotech pink sheet analysis is to determine its intrinsic value, which is an estimate of what CEN Biotech is worth, separate from its market price. There are two main types of CEN Biotech's stock analysis: fundamental analysis and technical analysis.
The CEN Biotech pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and CEN Biotech's ongoing operational relationships across important fundamental and technical indicators.
CEN |
CEN Pink Sheet Analysis Notes
About 54.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.41. CEN Biotech had not issued any dividends in recent years. CEN Biotech, Inc. focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products. The company was incorporated in 2013 and is based in Windsor, Canada. Cen Biotech operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4 people.The quote for CEN Biotech is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on CEN Biotech please contact Brian Payne at 519-419-4958 or go to https://www.cenbiotechinc.com.CEN Biotech Investment Alerts
| CEN Biotech generated a negative expected return over the last 90 days | |
| CEN Biotech has some characteristics of a very speculative penny stock | |
| CEN Biotech has accumulated 31.55 K in total debt. CEN Biotech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist CEN Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, CEN Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CEN Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CEN to invest in growth at high rates of return. When we think about CEN Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 626.87 K. Net Loss for the year was (18.9 M) with profit before overhead, payroll, taxes, and interest of 626.87 K. | |
| CEN Biotech has accumulated about 66.05 K in cash with (335.5 K) of positive cash flow from operations. | |
| Roughly 54.0% of the company shares are held by company insiders |
CEN Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.28 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CEN Biotech's market, we take the total number of its shares issued and multiply it by CEN Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.CEN Profitablity
The company has Profit Margin (PM) of (3.0) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.28) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.28.Technical Drivers
CEN Biotech technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.CEN Biotech Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in CEN Biotech price series with the more recent values given greater weights.
CEN Biotech Outstanding Bonds
CEN Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CEN Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CEN bonds can be classified according to their maturity, which is the date when CEN Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
CEN Biotech Debt to Cash Allocation
Many companies such as CEN Biotech, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
CEN Biotech has accumulated 31.55 K in total debt. CEN Biotech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist CEN Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, CEN Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CEN Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CEN to invest in growth at high rates of return. When we think about CEN Biotech's use of debt, we should always consider it together with cash and equity.CEN Biotech Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the CEN Biotech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of CEN Biotech, which in turn will lower the firm's financial flexibility.CEN Biotech Corporate Bonds Issued
Most CEN bonds can be classified according to their maturity, which is the date when CEN Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About CEN Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how CEN Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CEN shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as CEN Biotech. By using and applying CEN Pink Sheet analysis, traders can create a robust methodology for identifying CEN entry and exit points for their positions.
CEN Biotech, Inc. focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products. The company was incorporated in 2013 and is based in Windsor, Canada. Cen Biotech operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding CEN Biotech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
| All Next | Launch Module |
Complementary Tools for CEN Pink Sheet analysis
When running CEN Biotech's price analysis, check to measure CEN Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CEN Biotech is operating at the current time. Most of CEN Biotech's value examination focuses on studying past and present price action to predict the probability of CEN Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CEN Biotech's price. Additionally, you may evaluate how the addition of CEN Biotech to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |